You are on page 1of 1

Federal Register / Vol. 71, No.

97 / Friday, May 19, 2006 / Notices 29165

known as Emt and Tsk) and the Licensing Contact: Sally Hu, Ph.D., pharmaceutical composition, such as a
resulting decrease in HIV infectivity, M.B.A.; 301/435–5606; therapeutic or prophylactic product,
replication, and transcription for that modulates antigen presenting cell
exemplary purposes. Importantly, The invention describes the discovery activity, comprising contacting an APC
inhibition of Itk expression does not of short peptides, derived from the with a candidate ligand which interacts
affect the expression of HIV receptors natural peptide named indolicidin that with the APC, analyzing the activation
CCR5, CXCR4, or CD4. The current have an ability to inhibit HIV–1 state of the APC; and selecting ligands
technology could be used in integrase and exhibit antiviral activity. that activate a killer T cell in the
combination with therapeutics that In particular, this invention shows that absence of a helper T cells as the
target multiple stages of the virus life synthesized derivatives of the candidates for incorporation into the
cycle. indolicidin peptides named RIN–25 pharmaceutical. Also claimed are
This research is described, in part, in exhibit a significant higher anti-viral related methods where the ligand
the following: and anti-integrase activity when interacts with CD40 or where the APC
1. D Dombroski, R Houghtling, CM compared to the parent compound is a dendritic cell. The embodiments
Labno, J Burkhardt, and PL named RIN–42. HIV–1 integrase has a have several applications in the field of
Schwartzberg, ‘‘Kinase-independent good potential of being the next immunology, and enable to manufacture
functions for Itk in the regulation of Vav therapeutic target since HIV–1 integrase novel pharmaceuticals and vaccine
and the actin cytoskeleton,’’ J. Immunol. is essential for viral replication and components for the treatment and
174: 1385–1392, 2005. there is no cellular equivalent. Thus, prevention of cancer, systemic infection,
2. A Takesono, R Horai, M Mandai, D subject invention may be used in the and autoimmune responses.
Dombroski, and PL Schwartzberg, development of therapeutics for the The technology is further described in
‘‘Requirement for Tec family kinases in treatment of retroviral infections, such JP Ridge, F Di Rosa, and P Matzinger,
chemokine-induced migration and as AIDS, or other retroviral-related ‘‘A conditioned dendritic cell can be a
activation of Cdc42 and Rac,’’ Curr. diseases (i.e., cancer, immune temporal bridge between a CD4+ T-
Biol. 10:917–22, 2004. disorders). In addition, the novel helper and a T-killer cell,’’ Nature 1998
3. E Schaeffer, G Yap, CM Lewis, M peptides described in this invention Jun 4; 393(6684):474–8.
Czar, DW McVicar, AW Cheever, A may also have particular value when In addition to licensing, the
Sher, and PL Schwartzberg, ‘‘Mutation used in combination treatments with technology is available for further
of Tec family kinases alters T helper cell other antiviral therapies directed at development through collaborative
differentiation,’’ Nature Immunol. other viral targets, such as protease and research opportunities with the
2:1183–8, 2001. reverse transcriptase. inventors.
In addition to licensing, the Dated: May 11, 2006.
Identification of Candidate Ligands
technology is available for further David R. Sadowski,
which Modulate Antigen Presenting
development through collaborative Acting Director, Division of Technology
research opportunities with the Development and Transfer, Office of
inventors: The NHGRI, Genetic Disease Polly Matzinger, John P. Ridge (NIAID). Technology Transfer, National Institutes of
Research Branch/Cell Signalling U.S. Patent No. 6,680,176 issued 20 Jan Health.
Section, is seeking statements of 2004 (HHS Reference No. E–055– [FR Doc. E6–7627 Filed 5–18–06; 8:45 am]
capability or interest from parties 1999/0–US–01).
interested in collaborative research to Licensing Contact: Cristina
further develop, evaluate, or Thalhammer-Reyero; 301/435–4507;
commercialize the use of Tec family DEPARTMENT OF HEALTH AND
kinase inhibitors as a therapeutic target Available for licensing and HUMAN SERVICES
for HIV and other viral infections. commercial development are novel
Please contact Claire Driscoll, Director, biotechnological tools, prophylactics, National Institutes of Health
NHGRI Technology Transfer Office, at therapeutics, and methods for
301/402–2537 or cdriscol@mail.nih for modulating the activation state of an Center for Scientific Review; Amended
more information. antigen presenting cell (APC) and Notice of Meeting
thereby modulating the activation of a Notice is hereby given of a change in
Peptide Inhibitors of HIV–1 Integrase
killer T cell. The activation of a killer the meeting of the Center for Scientific
Useful for the Treatment of Retroviral
T cell can occur in a two cell complex Review Special Emphasis Panel, June
Infection and HIV
and two sequential steps: (a) In the first 13, 2006, 3 p.m. to June 13, 2006, 4:30
Peter P. Roller et al. (NCI) step, an APC stimulates a T helper T p.m., National Institutes of Health, 6701
U.S. Provisional Application No. 60/ cell, which in turn stimulates or Rockledge Drive, Bethesda, MD 20892
534,378 filed 06 Jan 2004 (HHS ‘‘superactivates’’ the APC to which was published in the Federal
Reference No. E–039–2004/0–US–01). differentiate to a state where it can Register on May 5, 2006, 71 FR 26550–
U.S. Provisional Application No. 60/ independently stimulate a killer T cell; 26552.
547,067 filed 25 Feb 2004 (HHS (b) In the second step, the APC The meeting will be held on June 15,
Reference No. E–039–2004/1–-US– encounters the killer T cell and 2006. The meeting time and location
01). stimulates it so that killer T cell priming remain the same. The meeting is closed
U.S. Provisional Application No. 60/ is achieved in a helper independent to the public.
599,856 filed 10 Aug 2004 (HHS fashion. The first step can be bypassed
Reference No. E–039–2004/2–US–01). altogether by viral infection or an Dated: May 11, 2006.
wwhite on PROD1PC61 with NOTICES

PCT Application No. PCT/US2004/ interaction with certain molecules at the Anna Snouffer,
42726 filed 21 Dec 2004 (HHS cell surface of APCs, such as CD40. Acting Director, Office of Federal Advisory
Reference No. E–039–2004/3–PCT– More specifically, the invention consists Committee Policy.
01), which published as WO 2005/ of a method of identifying a ligand as a [FR Doc. 06–4673 Filed 5–18–06; 8:45 am]
068492 on 29 Dec 2005. candidate for incorporation into a BILLING CODE 4140–01–M

VerDate Aug<31>2005 17:37 May 18, 2006 Jkt 208001 PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 E:\FR\FM\19MYN1.SGM 19MYN1